Medtronic (MDT) investor relations material

Business evolution and strategic direction

• Accelerated new product launches and portfolio actions, including the MiniMed IPO and renewed M&A activity, have driven business momentum over the past year.

• Confidence and positivity are high, with improved top-line performance and operational mechanisms starting to deliver results.

• Focus remains on building ecosystems and reinforcing product portfolios to drive future growth.

M&A and portfolio development

• Recent acquisitions like Scientia exemplify the strategy of adding complementary, synergistic technologies, especially in high-need areas like stroke care.

• M&A targets are typically medium-sized tuck-ins, with a focus on deals in the $1-3 billion range and high return thresholds.

• The approach includes both organic innovation and targeted acquisitions to create sticky product ecosystems.

Financial outlook and guidance

• Organic growth for fiscal 2026 is projected at 5.5%, with expectations for higher growth in 2027, excluding the impact of the 53rd week.

• Gross margins are improving due to operational efficiencies, pricing, and cost reductions, with leverage expected at the operating margin level.

• High single-digit EPS growth is targeted for next year, with dilution from recent M&A and diabetes business separation partially offset by the 53rd week.